Immunopathological effects of intravesical BCG therapy.
Prescott
S
S
Department of Surgery/Urology, Western General Hospital, Edinburgh, Scotland.
James
K
K
Hargreave
T B
TB
Chisholm
G D
GD
Smyth
J F
JF
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D001500:BCG Vaccine / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000145:classification; D001743:Urinary Bladder / Q000276:immunology / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D006684:HLA-DR Antigens